Upstream Bio, INC Form 4 insider transactions

Upstream Bio, Inc. CFO and COO Michael Gray reported a sale of 853 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Everett Rand, CEO of Upstream Bio, Inc., reported the sale of 2,095 shares of common stock on June 16, 2026, to cover tax withholding obligations related to restricted stock unit vesting.

Upstream Bio, Inc. officer Adam Houghton sold 700 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Upstream Bio's Chief Medical Officer, Aaron Deykin, sold 895 shares of common stock to cover tax withholding obligations related to vesting restricted stock units.

Upstream Bio, Inc. reports that General Counsel Allison Ambrose sold 477 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Director Marcella K. Ruddy was granted 17,096 stock options in Upstream Bio, Inc. as part of standard equity compensation.

Director Ronald C. Renaud Jr. was granted 17,096 stock options in Upstream Bio, Inc. as part of standard equity compensation.

Director Harold Edward Fleming was granted 17,096 stock options in Upstream Bio, Inc. to be held for the benefit of Enavate Sciences, LP.

Director Daniella Beckman was granted 17,096 stock options in Upstream Bio, Inc. as part of standard equity compensation.

Director Liam Ratcliffe was granted 17,096 stock options in Upstream Bio, Inc. as part of standard equity compensation.

Director Erez Chimovits was granted 17,096 stock options in Upstream Bio, Inc. as part of standard compensation.

Upstream Bio's CFO and COO, Michael Gray, sold 852 shares of common stock to cover tax withholding obligations related to RSU vesting.

Upstream Bio's Chief Medical Officer, Aaron Deykin, sold 894 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Upstream Bio's CEO, Everett Rand Sutherland, sold 2,093 shares of common stock at $9.29 per share to cover tax withholding obligations related to vested restricted stock units.

Upstream Bio's General Counsel, Allison Ambrose, sold 475 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Upstream Bio's Chief Business Officer, Adam Houghton, sold 699 shares of common stock at $9.29 per share to cover tax withholding obligations related to vested restricted stock units.

Upstream Bio's CFO and COO, Michael Gray, was granted 30,500 restricted stock units and options to purchase 91,500 shares of common stock.

Upstream Bio's Chief Medical Officer, Aaron Deykin, was granted 32,000 restricted stock units and options for 96,000 shares of common stock.

Upstream Bio's General Counsel, Allison Ambrose, was granted 17,000 restricted stock units and options to purchase 51,000 shares of common stock.

Upstream Bio's Chief Business Officer, Adam Houghton, received grants of 25,000 restricted stock units and options for 75,000 shares.

Upstream Bio, Inc. CEO Everett Rand Sutherland was granted 75,000 restricted stock units and options for 225,000 shares, aligning executive incentives with company performance.

Upstream Bio, Inc. Director Ronald C. Renaud Jr. was granted 17,096 stock options with an exercise price of $11.59 per share, vesting over approximately one year.

Upstream Bio, Inc. Director and 10% Owner Erez Chimovits was granted 17,096 stock options with a $11.59 exercise price, subject to vesting and an obligation to transfer benefits to OrbiMed entities.

Upstream Bio, Inc. Director Marcella K. Ruddy was granted 17,096 stock options with an exercise price of $11.59, vesting based on service or the next annual meeting.

Upstream Bio, Inc. Director Daniella Beckman was granted 17,096 stock options with an exercise price of $11.59, vesting upon continued service.

Upstream Bio, Inc. director Harold Edward Fleming was granted 17,096 stock options with an exercise price of $11.59, but disclaimed personal beneficial ownership, holding them for the benefit of Enavate Sciences, LP.

Upstream Bio, Inc. Director Liam Ratcliffe was granted 17,096 stock options with an exercise price of $11.59, vesting over time and subject to continued service.

Upstream Bio's CEO, Everett Rand Sutherland, was granted stock options for 500,000 shares of common stock on February 6, 2025, according to a Form 4 filing.

Michael Gray, CFO and COO of Upstream Bio, Inc., reports the acquisition of stock options.

Adam Houghton, Chief Business Officer of Upstream Bio, Inc., was granted stock options for 140,000 shares on February 6, 2025, according to a recent SEC filing.